Bentham Science Logo

Track Your Manuscript:


Current Cancer Drug Targets

Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access

Contents

Current Cancer Drug Targets , Volume 20 - Number 11






Research Article

Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma

, 20(11): 875 - 886

Yingyi Wang, Bao Jin, Na Zhou, Zhao Sun, Jiayi Li, Qiao Chen, Xiangan Wu, Yi Zhou, Yue Shi, Xin Lu, Xinting Sang, Yilei Mao, Shunda Du*, Wenze Wang* and Chunmei Bai*


DOI: 10.2174/1568009620999200918121456


Clinical Trial

Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study

, 20(11): 887 - 895

Martina Catalano, Giandomenico Roviello*, Raffaele Conca, Alberto D’Angelo, Valeria Emma Palmieri, Benedetta Panella, Roberto Petrioli, Anna Ianza, Stefania Nobili, Enrico Mini and Monica Ramello


DOI: 10.2174/1568009620999200918122426




Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
View Full Editorial Board

COPE Compliant

Cope Logo

Journal History

Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.

Advertisement

Mechanisms-of-Metabolic-Disorders-(MMD)

Related Journals

Related eBooks

eBooks Catalog